Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Oncocyte To Announce Second Quarter 2023 Financial Results By: ACCESSWIRE August 03, 2023 at 08:00 AM EDT Conference Call and Webcast on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA / ACCESSWIRE / August 3, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, prior to the U.S. market open. The company will host a conference call and webcast on Thursday, August 10, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (877) 317-6789 for domestic callers and (412) 317-6789 for international callers. Once dialed in ask to be joined to the Oncocyte Corporation call. The live webinar of the call may be accessed by visiting the "Events & Presentation" section of the Company's website at https://investors.oncocyte.com. A replay of the webinar will be available on the Company's website shortly after the conclusion of the call. About OncocyteOncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/ VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation. CONTACT:Stephanie PrincePCG Advisory(646) 863-6341sprince@pcgadvisory.com SOURCE: Oncocyte via PRISM Mediawire, LLC View source version on accesswire.com: https://www.accesswire.com/771952/Oncocyte-To-Announce-Second-Quarter-2023-Financial-Results Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Oncocyte To Announce Second Quarter 2023 Financial Results By: ACCESSWIRE August 03, 2023 at 08:00 AM EDT Conference Call and Webcast on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA / ACCESSWIRE / August 3, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, prior to the U.S. market open. The company will host a conference call and webcast on Thursday, August 10, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (877) 317-6789 for domestic callers and (412) 317-6789 for international callers. Once dialed in ask to be joined to the Oncocyte Corporation call. The live webinar of the call may be accessed by visiting the "Events & Presentation" section of the Company's website at https://investors.oncocyte.com. A replay of the webinar will be available on the Company's website shortly after the conclusion of the call. About OncocyteOncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/ VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation. CONTACT:Stephanie PrincePCG Advisory(646) 863-6341sprince@pcgadvisory.com SOURCE: Oncocyte via PRISM Mediawire, LLC View source version on accesswire.com: https://www.accesswire.com/771952/Oncocyte-To-Announce-Second-Quarter-2023-Financial-Results
Conference Call and Webcast on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA / ACCESSWIRE / August 3, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, prior to the U.S. market open. The company will host a conference call and webcast on Thursday, August 10, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (877) 317-6789 for domestic callers and (412) 317-6789 for international callers. Once dialed in ask to be joined to the Oncocyte Corporation call. The live webinar of the call may be accessed by visiting the "Events & Presentation" section of the Company's website at https://investors.oncocyte.com. A replay of the webinar will be available on the Company's website shortly after the conclusion of the call. About OncocyteOncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/ VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation. CONTACT:Stephanie PrincePCG Advisory(646) 863-6341sprince@pcgadvisory.com SOURCE: Oncocyte via PRISM Mediawire, LLC View source version on accesswire.com: https://www.accesswire.com/771952/Oncocyte-To-Announce-Second-Quarter-2023-Financial-Results